Multiple roles of toll-like receptor 4 in colorectal cancer

Frontiers in Immunology

Volumn 5, Issue JUL, 2014, Pages

  Yesudhas, Dhanusha ^a   Gosu, Vijayakumar ^a   Anwar, Muhammad Ayaz ^a   Choi, Sangdun ^a  

^a Ajou University   (South Korea)

Author keywords

Colorectal cancer; Immune response; Inflammation; Ligand; Toll like receptor 4

Indexed keywords

EID: 84905641569     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00334     Document Type: Review

References (128)

1. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol (2004) 4(7):499-511. doi: 10.1038/nri1391
2. Oldenburg M, Kruger A, Ferstl R, Kaufmann A, Nees G, Sigmund A, et al. TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modification. Science (2012) 337(6098):1111-5. doi:10.1126/science.1220363
3. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol (2010) 11(5):373-84. doi:10.1038/ni.1863
4. Takeuchi O, Kaufmann A, Grote K, Kawai T, Hoshino K, Morr M, et al. Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a toll-like receptor 2- and MyD88-dependent signaling pathway. J Immunol (2000) 164(2):554-7. doi:10.4049/jimmunol.164.2.554
5. Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z, et al. Cutting edge: role of toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol (2002) 169(1):10-4. doi:10.4049/jimmunol.169.1.10
6. Takeuchi O, Kawai T, Muhlradt PF, Morr M, Radolf JD, Zychlinsky A, et al. Discrimination of bacterial lipoproteins by toll-like receptor 6. Int Immunol (2001) 13(7):933-40. doi:10.1093/intimm/13.7.933
7. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by toll-like receptor 3. Nature (2001) 413(6857):732-8. doi:10.1038/35099560
8. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science (1998) 282(5396):2085-8. doi:10.1126/science.282.5396.2085
9. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, et al. The innate immune response to bacterial flagellin is mediated by toll-like receptor 5. Nature (2001) 410(6832):1099-103. doi:10.1038/35074106
10. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis E, Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science (2004) 303(5663):1529-31. doi:10.1126/science.1093616
11. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science (2004) 303(5663):1526-9. doi:10.1126/science.1093620
12. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. A toll-like receptor recognizes bacterial DNA. Nature (2000) 408(6813):740-5. doi:10.1038/35047123
13. Krug A, French AR, Barchet W, Fischer JA, Dzionek A, Pingel JT, et al. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity (2004) 21(1):107-19. doi:10.1016/j.immuni.2004.06.007
14. Gosu V, Basith S, Kwon OP, Choi S. Therapeutic applications of nucleic acids and their analogues in toll-like receptor signaling. Molecules (2012) 17(11):13503-29. doi:10.3390/molecules171113503
15. Lavelle EC, Murphy C, O'Neill LA, Creagh EM. The role of TLRs, NLRs, and RLRs in mucosal innate immunity and homeostasis. Mucosal Immunol (2010) 3(1):17-28. doi:10.1038/mi.2009.124
16. Rakoff-Nahoum S, Medzhitov R. Role of toll-like receptors in tissue repair and tumorigenesis. Biochemistry (Mosc) (2008) 73(5):555-61. doi:10.1134/S0006297908050088
17. So EY, Ouchi T. The application of toll like receptors for cancer therapy. Int J Biol Sci (2010) 6(7):675-81. doi:10.7150/ijbs.6.675
18. Keogh B, Parker AE. Toll-like receptors as targets for immune disorders. Trends Pharmacol Sci (2011) 32(7):435-42. doi:10.1016/j.tips.2011.03.008
19. Shi Z, Cai Z, Sanchez A, Zhang T, Wen S, Wang J, et al. A novel toll-like receptor that recognizes vesicular stomatitis virus. J Biol Chem (2011) 286(6):4517-24. doi:10.1074/jbc.M110.159590
20. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature (2006) 441(7092):431-6. doi:10.1038/nature04870
21. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol (2005) 5(10):749-59. doi:10.1038/nri1703
22. Frolova L, Drastich P, Rossmann P, Klimesova K, Tlaskalova-Hogenova H. Expression of toll-like receptor 2 (TLR2), TLR4, and CD14 in biopsy samples of patients with inflammatory bowel diseases: upregulated expression of TLR2 in terminal ileum of patients with ulcerative colitis. J Histochem Cytochem (2008) 56(3):267-74. doi:10.1369/jhc.7A7303.2007
23. Smith RA, Brooks D, Cokkinides V, Saslow D, Brawley OW. Cancer screening in the United States, 2013. CA Cancer J Clin (2013) 63(2):87-105. doi:10.3322/caac.21174
24. Tenesa A, Dunlop MG. New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet (2009) 10(6):353-8. doi:10.1038/nrg2574
25. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology (2010) 138(6): 2101-14.e5. doi:10.1053/j.gastro.2010.01.058
26. Adelstein BA, Macaskill P, Chan SF, Katelaris PH, Irwig L. Most bowel cancer symptoms do not indicate colorectal cancer and polyps: a systematic review. BMC Gastroenterol (2011) 11:65. doi:10.1186/1471-230X-11-65
27. Evans JT, Cluff CW, Johnson DA, Lacy MJ, Persing DH, Baldridge JR. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev Vaccines (2003) 2(2):219-29. doi:10.1586/14760584.2.2.219
28. Blasius AL, Beutler B. Intracellular toll-like receptors. Immunity (2010) 32(3):305-15. doi:10.1016/j.immuni.2010.03.012
29. Gosu V, Basith S, Durai P, Choi S. Molecular evolution and structural features of IRAK family members. PLoS One (2012) 7(11):e49771. doi:10.1371/journal.pone.0049771
30. Chen ZJ. Ubiquitin signalling in the NF-κB pathway. Nat Cell Biol (2005) 7(8):758-65. doi:10.1038/ncb0805-758
31. Sato S, Sanjo H, Takeda K, Ninomiya-Tsuji J, Yamamoto M, Kawai T, et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol (2005) 6(11):1087-95. doi:10.1038/ni1255
32. Takeda K, Akira S. TLR signaling pathways. Semin Immunol (2004) 16(1):3-9. doi:10.1016/j.smim.2003.10.003
33. Moossavi S, Rezaei N. Toll-like receptor signalling and their therapeutic targeting in colorectal cancer. Int Immunopharmacol (2013) 16(2):199-209. doi:10.1016/j.intimp.2013.03.017
34. Abreu MT. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol (2010) 10(2):131-44. doi:10.1038/nri2707
35. Khan MA, Ma C, Knodler LA, Valdez Y, Rosenberger CM, Deng W, et al. Toll-like receptor 4 contributes to colitis development but not to host defense during Citrobacter rodentium infection in mice. Infect Immun (2006) 74(5):2522-36. doi:10.1128/IAI.74.5.2522-2536.2006
36. Lebeis SL, Bommarius B, Parkos CA, Sherman MA, Kalman D. TLR signaling mediated by MyD88 is required for a protective innate immune response by neutrophils to Citrobacter rodentium. J Immunol (2013) 179:566-77. doi:10.4049/jimmunol.179.1.566.
37. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun (2000) 68(12):7010-7. doi:10.1128/IAI.68.12.7010-7017.2000
38. Gewirtz AT, Navas TA, Lyons S, Godowski PJ, Madara JL. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol (2001) 167(4):1882-5. doi:10.4049/jimmunol.167.4.1882
39. Grimm M, Kim M, Rosenwald A, Heemann U, Germer C-T, Waaga-Gasser AM, et al. Toll-like receptor (TLR) 7 and TLR8 expression on CD133 + cells in colorectal cancer points to a specific role for inflammation-induced TLRs in tumourigenesis and tumour progression. Eur J Cancer (2010) 46(15):2849-57. doi:10.1016/j.ejca.2010.07.017
40. Medzhitov R. Origin and physiological roles of inflammation. Nature (2008) 454(7203):428-35. doi:10.1038/nature07201
41. Liew FY, Xu D, Brint EK, O'Neill LA. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol (2005) 5(6):446-58. doi:10.1038/nri1630
42. Anwar MA, Basith S, Choi S. Negative regulatory approaches to the attenuation of toll-like receptor signaling. Exp Mol Med (2013) 45:e11. doi:10.1038/emm.2013.28
43. Lebeer S, Vanderleyden J, De Keersmaecker SC. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat Rev Microbiol (2010) 8(3):171-84. doi:10.1038/nrmicro2297
44. Hooper LV, Macpherson AJ. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol (2010) 10(3):159-69. doi:10.1038/nri2710
45. Xiao H, Gulen MF, Qin J, Yao J, Bulek K, Kish D, et al. The toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. Immunity (2007) 26(4):461-75. doi:10.1016/j.immuni.2007.02.012
46. Rakoff NS, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell (2004) 118(2):229-41. doi:10.1016/j.cell.2004.07.002
47. Salcedo R, Worschech A, Cardone M, Jones Y, Gyulai Z, Dai RM, et al. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med (2010) 207(8):1625-36. doi:10.1084/jem.20100199
48. Clevers H. At the crossroads of inflammation and cancer. Cell (2004) 118(6):671-4. doi:10.1016/j.cell.2004.09.005
49. Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer (2013) 13(11):759-71. doi:10.1038/nrc3611
50. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology (2011) 140(6):1807-16. doi:10.1053/j.gastro.2011.01.057
51. Uronis JM, Mühlbauer M, Herfarth HH, Rubinas TC, Jones GS, Jobin C. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS One (2009) 4(6):e6026. doi:10.1371/journal.pone.0006026
52. Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci U S A (2008) 105(2):652-6. doi:10.1073/pnas.0708594105
53. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer (2009) 9(5):361-71. doi:10.1038/nrc2628
54. Govind S. Control of development and immunity by rel transcription factors in Drosophila. Oncogene (1999) 18(49):6875-87. doi:10.1038/sj.onc.1203223
55. Perkins ND. NF-κB: tumor promoter or suppressor? Trends Cell Biol (2004) 14(2):64-9. doi:10.1016/j.tcb.2003.12.004
56. Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 133(6):1869-81. doi:10.1053/j.gastro.2007.09.008
57. Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest (2008) 118(2):560-70. doi:10.1172/JCI32453
58. Oshima H, Oshima M. The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models. J Gastroenterol (2012) 47(2):97-106. doi:10.1007/s00535-011-0523-6
59. Ogino S, Kirkner GJ, Nosho K, Irahara N, Kure S, Shima K, et al. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res (2008) 14(24):8221-7. doi:10.1158/1078-0432.CCR-08-1841
60. Leaphart CL, Cavallo J, Gribar SC, Cetin S, Li J, Branca MF, et al. A critical role for TLR4 in the pathogenesis of necrotizing enterocolitis by modulating intestinal injury and repair. J Immunol (2007) 179(7):4808-20. doi:10.4049/jimmunol.179.7.4808
61. Jilling T, Simon D, Lu J, Meng FJ, Li D, Schy R, et al. The roles of bacteria and TLR4 in rat and murine models of necrotizing enterocolitis. J Immunol (2006) 177(5):3273-82. doi:10.4049/jimmunol.177.5.3273
62. Otte JM, Cario E, Podolsky DK. Mechanisms of cross hyporesponsiveness to toll-like receptor bacterial ligands in intestinal epithelial cells. Gastroenterology (2004) 126(4):1054-70. doi:10.1053/j.gastro.2004.01.007
63. Abreu MT, Vora P, Faure E, Thomas LS, Arnold ET, Arditi M. Decreased expression of toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol (2001) 167(3):1609-16. doi:10.4049/jimmunol.167.3.1609
64. Suzuki M, Hisamatsu T, Podolsky DK. Gamma interferon augments the intracellular pathway for lipopolysaccharide (LPS) recognition in human intestinal epithelial cells through coordinated up-regulation of LPS uptake and expression of the intracellular toll-like receptor 4-MD-2 complex. Infect Immun (2003) 71(6):3503-11. doi:10.1128/IAI.71.6.3503-3511.2003
65. Abreu MT, Arnold ET, Thomas LS, Gonsky R, Zhou Y, Hu B, et al. TLR4 and MD-2 expression is regulated by immune-mediated signals in human intestinal epithelial cells. J Biol Chem (2002) 277(23):20431-7. doi:10.1074/jbc.M110333200
66. Hornef MW, Frisan T, Vandewalle A, Normark S, Richter-Dahlfors A. Toll-like receptor 4 resides in the Golgi apparatus and colocalizes with internalized lipopolysaccharide in intestinal epithelial cells. J Exp Med (2002) 195(5):559-70. doi:10.1084/jem.20011788
67. Doan HQ, Bowen KA, Jackson LA, Evers BM. Toll-like receptor 4 activation increases Akt phosphorylation in colon cancer cells. Anticancer Res (2009) 29(7):2473-8.
68. Fukata M, Chen A, Klepper A, Krishnareddy S, Vamadevan AS, Thomas LS, et al. Cox-2 is regulated by toll-like receptor-4 (TLR4) signaling: role in proliferation and apoptosis in the intestine. Gastroenterology (2006) 131(3):862-77. doi:10.1053/j.gastro.2006.06.017
69. Cammarota R, Bertolini V, Pennesi G, Bucci EO, Gottardi O, Garlanda C, et al. The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker. J Transl Med (2010) 8(1):112. doi:10.1186/1479-5876-8-112
70. Fukata M, Abreu MT. TLR4 signalling in the intestine in health and disease. Biochem Soc Trans (2007) 35(Pt 6):1473-8. doi:10.1042/BST0351473
71. Abreu MT, Thomas LS, Arnold ET, Lukasek K, Michelsen KS, Arditi M. TLR signaling at the intestinal epithelial interface. J Endotoxin Res (2003) 9(5):322-30. doi:10.1179/096805103225002593
72. Katakura K, Lee J, Rachmilewitz D, Li G, Eckmann L, Raz E. Toll-like receptor 9 - induced type I IFN protects mice from experimental colitis. J Clin Invest (2005) 115(3):695-702. doi:10.1172/JCI200522996C1
73. Laird MH, Rhee SH, Perkins DJ, Medvedev AE, Piao W, Fenton MJ, et al. TLR4/MyD88/PI3K interactions regulate TLR4 signaling. J Leukoc Biol (2009) 85(6):966-77. doi:10.1189/jlb.1208763
74. Sheng H, Shao J, Townsend CM Jr, Evers BM. Phosphatidylinositol 3-kinase mediates proliferative signals in intestinal epithelial cells. Gut (2003) 52(10):1472-8. doi:10.1136/gut.52.10.1472
75. Somanath PR, Kandel ES, Hay N, Byzova TV. Akt1 signaling regulates integrin activation, matrix recognition, and fibronectin assembly. J Biol Chem (2007) 282(31):22964-76. doi:10.1074/jbc.M700241200
76. Hsu RY, Chan CH, Spicer JD, Rousseau MC, Giannias B, Rousseau S, et al. LPS-induced TLR4 signaling in human colorectal cancer cells increases beta1 integrin-mediated cell adhesion and liver metastasis. Cancer Res (2011) 71(5):1989-98. doi:10.1158/0008-5472.CAN-10-2833
77. Earl TM, Nicoud IB, Pierce JM, Wright JP, Majoras NE, Rubin JE, et al. Silencing of TLR4 decreases liver tumor burden in a murine model of colorectal metastasis and hepatic steatosis. Ann Surg Oncol (2009) 16(4):1043-50. doi:10.1245/s10434-009-0325-8
78. Killeen S, Wang J, Andrews E, Redmond H. Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF-?B-dependent activation of the urokinase plasminogen activator system. Br J Cancer (2009) 100(10):1589-602. doi:10.1038/sj.bjc.6604942
79. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest (2001) 107(3):241-6. doi:10.1172/JCI11991
80. Hatta Y, Koeffler HP. Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL). Leukemia (2002) 16(6):1069-85. doi:10.1038/sj.leu.2402458
81. Ryan KM, Ernst MK, Rice NR, Vousden KH. Role of NF-kappaB in p53-mediated programmed cell death. Nature (2000) 404(6780):892-7. doi:10.1038/35009130
82. Wang EL, Qian ZR, Nakasono M, Tanahashi T, Yoshimoto K, Bando Y, et al. High expression of toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer (2010) 102(5):908-15. doi:10.1038/sj.bjc.6605558
83. Rakoff NS, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science (2007) 317(5834):124-7. doi:10.1126/science.1140488
84. Lee SH, Hu LL, Gonzalez-Navajas J, Seo GS, Shen C, Brick J, et al. ERK activation drives intestinal tumorigenesis in Apc(min/+) mice. Nat Med (2010) 16(6):665-70. doi:10.1038/nm.2143
85. Gustafson WC, Weiss WA. Myc proteins as therapeutic targets. Oncogene (2010) 29(9):1249-59. doi:10.1038/onc.2009.512
86. Wilkins JA, Sansom OJ. C-Myc is a critical mediator of the phenotypes of Apc loss in the intestine. Cancer Res (2008) 68(13):4963-6. doi:10.1158/0008-5472.CAN-07-5558
87. Fukata M, Abreu MT. Microflora in colorectal cancer: a friend to fear. Nat Med (2010) 16(6):639-41. doi:10.1038/nm0610-639
88. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell (1991) 66(3):589-600. doi:10.1016/0092-8674(81)90021-0
89. Goss KH, Groden J. Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol (2000) 18(9):1967-79.
90. Opal SM, Esmon CT. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care (2002) 7(1):23. doi:10.1186/cc1854
91. Hennessy EJ, Parker AE, O'Neill LA. Targeting toll-like receptors: emerging therapeutics? Nat Rev Drug Discov (2010) 9(4):293-307. doi:10.1038/nrd3203
92. Slattery ML, Herrick JS, Bondurant KL, Wolff RK. Toll-like receptor genes and their association with colon and rectal cancer development and prognosis. Int J Cancer (2012) 130(12):2974-80. doi:10.1002/ijc.26314
93. Pimentel-Nunes P, Teixeira AL, Pereira C, Gomes M, Brandao C, Rodrigues C, et al. Functional polymorphisms of toll-like receptors 2 and 4 alter the risk for colorectal carcinoma in Europeans. Dig Liver Dis (2013) 45(1):63-9. doi:10.1016/j.dld.2012.08.006
94. Omrane I, Baroudi O, Kourda N, Bignon YJ, Uhrhammer N, Desrichard A, et al. Positive link between variant toll-like receptor 4 (Asp299Gly and Thr399Ile) and colorectal cancer patients with advanced stage and lymph node metastasis. Tumour Biol (2013) 35(1):545-51. doi:10.1007/s13277-013-1075-6
95. Mockenhaupt FP, Cramer JP, Hamann L, Stegemann MS, Eckert J, Oh NR, et al. Toll-like receptor (TLR) polymorphisms in African children: common TLR-4 variants predispose to severe malaria. Proc Natl Acad Sci U S A (2006) 103(1):177-82. doi:10.1073/pnas.0506803102
96. Garza-Gonzalez E, Bosques-Padilla FJ, Mendoza-Ibarra SI, Flores-Gutierrez JP, Maldonado-Garza HJ, Perez-Perez GI. Assessment of the toll-like receptor 4 Asp299Gly, Thr399Ile and interleukin-8-251 polymorphisms in the risk for the development of distal gastric cancer. BMC Cancer (2007) 7(1):70. doi:10.1186/1471-2407-7-70
97. Ferwerda B, Mccall MB, Verheijen K, Kullberg BJ, Van Der Ven AJ, Van Der Meer JW, et al. Functional consequences of toll-like receptor 4 polymorphisms. Mol Med (2008) 14(5-6):346-52. doi:10.2119/2007-00135.Ferwerda
98. Boraska Jelavic T, Barisic M, Drmic Hofman I, Boraska V, Vrdoljak E, Peruzovic M, et al. Microsatelite GT polymorphism in the toll-like receptor 2 is associated with colorectal cancer. Clin Genet (2006) 70(2):156-60. doi:10.1111/j.1399-0004.2006.00651.x
99. Li XX, Sun GP, Meng J, Li X, Tang YX, Li Z, et al. Role of toll-like receptor 4 in colorectal carcinogenesis: a meta-analysis. PLoS One (2014) 9(4):e93904. doi:10.1371/journal.pone.0093904
100. Santini D, Angeletti S, Ruzzo A, Dicuonzo G, Galluzzo S, Vincenzi B, et al. Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes. Clin Exp Immunol (2008) 154(3):360-4. doi:10.1111/j.1365-2249.2008.03776.x
101. Zhao X, Kang S, Liu L, Zhang D. Correlation of Asp299Gly and Thr399Ile polymorphisms in toll-like receptor 4 gene with digestive cancer risk: a meta-analysis. Biomed Rep (2013) 1(2):294-302. doi:10.3892/br.2012.32
102. Castro FA, Forsti A, Buch S, Kalthoff H, Krauss C, Bauer M, et al. TLR-3 polymorphism is an independent prognostic marker for stage II colorectal cancer. Eur J Cancer (2011) 47(8):1203-10. doi:10.1016/j.ejca.2010.12.011
103. Tsilidis KK, Helzlsouer KJ, Smith MW, Grinberg V, Hoffman-Bolton J, Clipp SL, et al. Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer. Cancer Causes Control (2009) 20(9):1739-51. doi:10.1007/s10552-009-9427-7
104. Guo Q, Zhu J, Xia B. Polymorphism of CD14 gene but not the mutation of TLR4 gene is associated with colorectal cancer in Chinese patients. J Gastroenterol Hepatol (2006) 21(1 Pt 1):92-7. doi:10.1111/j.1440-1746.2005.04156.x
105. Chen R, Luo FK, Wang YL, Tang JL, Liu YS. LBP and CD14 polymorphisms correlate with increased colorectal carcinoma risk in Han Chinese. World J Gastroenterol (2011) 17(18):2326-31. doi:10.3748/wjg.v17.i18.2326
106. Landi S, Gemignani F, Bottari F, Gioia-Patricola L, Guino E, Cambray M, et al. Polymorphisms within inflammatory genes and colorectal cancer. J Negat Results Biomed (2006) 5:15. doi:10.1186/1477-5751-5-15
107. Davoodi H, Seow HF. Variant toll-like receptor4 (Asp299Gly and Thr399Ile alleles) and toll-like receptor2 (Arg753Gln and Arg677Trp alleles) in colorectal cancer. Iran J Allergy Asthma Immunol (2011) 10(2):91-9. doi:010.02/ijaai.9199
108. Kutikhin AG, Yuzhalin AE, Volkov AN, Zhivotovskiy AS, Brusina EB. Correlation between genetic polymorphisms within IL-1B and TLR4 genes and cancer risk in a Russian population: a case-control study. Tumour Biol (2014) 35(5):4821-30. doi:10.1007/s13277-014-1633-6
109. Takahashi K, Sugi Y, Hosono A, Kaminogawa S. Epigenetic regulation of TLR4 gene expression in intestinal epithelial cells for the maintenance of intestinal homeostasis. J Immunol (2009) 183(10):6522-9. doi:10.4049/jimmunol.0901271
110. Govind CK, Ginsburg D, Hinnebusch AG. Measuring dynamic changes in histone modifications and nucleosome density during activated transcription in budding yeast. Methods Mol Biol (2012) 833:15-27. doi:10.1007/978-1-61779-477-3_2
111. Takahashi K, Sugi Y, Nakano K, Tsuda M, Kurihara K, Hosono A, et al. Epigenetic control of the host gene by commensal bacteria in large intestinal epithelial cells. J Biol Chem (2011) 286(41):35755-62. doi:10.1074/jbc.M111.271007
112. Davie JR. Inhibition of histone deacetylase activity by butyrate. J Nutr (2003) 133(7 Suppl):2485S-93S.
113. Waldecker M, Kautenburger T, Daumann H, Busch C, Schrenk D. Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon. J Nutr Biochem (2008) 19(9):587-93. doi:10.1016/j.jnutbio.2007.08.002
114. Vamadevan AS, Fukata M, Arnold ET, Thomas LS, Hsu D, Abreu MT. Regulation of toll-like receptor 4-associated MD-2 in intestinal epithelial cells: a comprehensive analysis. Innate Immun (2010) 16(2):93-103. doi:10.1177/1753425909339231
115. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with toll-like receptor agonists and antagonists. Nat Med (2007) 13(5):552-9. doi:10.1038/nm1589
116. Akira S. Mammalian toll-like receptors. Curr Opin Immunol (2003) 15(1):5-11. doi:10.1016/S0952-7915(03)00005-0
117. Mackensen A, Galanos C, Engelhardt R. Treatment of cancer patients with endotoxin induces release of endogenous cytokines. Pathobiology (1991) 59(4):264-7. doi:10.1159/000163659
118. Engelhardt R, Mackensen A, Galanos C. Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients. Cancer Res (1991) 51(10):2524-30.
119. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, et al. Trial watch: experimental toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1(5):699-716. doi:10.4161/onci.20696
120. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science (2007) 316(5831):1628-32. doi:10.1126/science.1138963
121. Persing DH, Coler RN, Lacy MJ, Johnson DA, Baldridge JR, Hershberg RM, et al. Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol (2002) 10(10):s32-7. doi:10.1016/S0966-842X(02)02426-5
122. Krieg AM. Toll-free vaccines? Nat Biotechnol (2007) 25(3):303-5. doi:10.1038/nbt0307-303
123. Basith S, Manavalan B, Yoo TH, Kim SG, Choi S. Roles of toll-like receptors in cancer: a double-edged sword for defense and offense. Arch Pharm Res (2012) 35(8):1297-316. doi:10.1007/s12272-012-0802-7
124. D'Agostini C, Pica F, Febbraro G, Grelli S, Chiavaroli C, Garaci E. Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions. Int Immunopharmacol (2005) 5(7-8):1205-12. doi:10.1016/j.intimp.2005.02.013
125. De Ridder M, Verovski VN, Chiavaroli C, Van Den Berge DL, Monsaert C, Law K, et al. The radiosensitizing effect of immunoadjuvant OM-174 requires cooperation between immune and tumor cells through interferon-gamma and inducible nitric oxide synthase. Int J Radiat Oncol Biol Phys (2006) 66(5):1473-80. doi:10.1016/j.ijrobp.2006.07.1381
126. Isambert N, Fumoleau P, Paul C, Ferrand C, Zanetta S, Bauer J, et al. Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer (2013) 13:172. doi:10.1186/1471-2407-13-172
127. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulieres D, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol (2005) 23(27):6674-81. doi:10.1200/JCO.2005.13.011
128. Kroemer G, Zitvogel L, Galluzzi L. Victories and deceptions in tumor immunology: Stimuvax. Oncoimmunology (2013) 2(1):e23687. doi:10.4161/onci.23687